Galectin raises $23.9 million

Galectin Therapeutics Inc. (NASDAQ:GALT) said on Friday that it raised $23.9 million in an at-the-market program with MLV. From Oct. 28, 2013, through Jan. 9, the company sold 2.4 million shares at an average price of $9.99. Galectin jumped $1.61 (12%) to $15.10 on Friday, buoyed in part by positive clinical news from fellow hepatic company Intercept Pharmaceuticals Inc. (NASDAQ:ICPT). Galectin has gained $6.63 (78%) since Intercept made the announcement on Thursday (see below). ...